Rosetta Genomics (ROSG) Earns News Impact Score of 0.24

Media coverage about Rosetta Genomics (NASDAQ:ROSG) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Rosetta Genomics earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 47.6538786895899 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Separately, Barrington Research downgraded Rosetta Genomics from an “outperform” rating to a “market perform” rating in a research report on Monday, December 18th.

Rosetta Genomics (NASDAQ ROSG) remained flat at $$0.58 during trading hours on Friday. 63,498 shares of the company traded hands, compared to its average volume of 155,002. Rosetta Genomics has a 12 month low of $0.48 and a 12 month high of $6.72. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.10 and a quick ratio of 2.10.

TRADEMARK VIOLATION WARNING: “Rosetta Genomics (ROSG) Earns News Impact Score of 0.24” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at

Rosetta Genomics Company Profile

Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH).

Insider Buying and Selling by Quarter for Rosetta Genomics (NASDAQ:ROSG)

Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit